DXR logo

Daxor (DXR) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 July 1983

Indexes:

Not included

Description:

Daxor Corporation, known as DXR, specializes in medical technology. They develop innovative blood volume measurement systems to help diagnose and manage various health conditions. Their products aim to improve patient care by providing accurate data for better treatment decisions in hospitals and clinics.

Key Details

Price

$9.45

Annual Revenue

$1.28 M(-79.71% YoY)

Annual EPS

$0.14(-83.91% YoY)

Beta

-0.18

Events Calendar

Earnings

Next earnings date:

Mar 25, 2025

Recent quarterly earnings:

Aug 29, 2024

Recent annual earnings:

Mar 25, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Jan 05, 2018
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

09 Sept '24 Ascendiant Capital
Buy
29 July '19 Maxim Group
Buy
16 May '19 Ascendiant Capital
Buy
16 May '19 Ascendiant
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
DXR
globenewswire.com08 October 2024

Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The summit is being held from October 15 – 17, 2024.

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
DXR
globenewswire.com27 September 2024

Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a strategic update to its regulatory approach for its novel diagnostic blood volume analyzer platform.

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
DXR
globenewswire.com19 September 2024

Oak Ridge, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces its participation in the Annual Scientific Meeting of the Heart Failure Society of America (HFSA), taking place September 27-30 at the Georgia World Congress Center and Signia by Hilton Atlanta. The event will gather the world's top heart failure experts.

Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
DXR
globenewswire.com04 September 2024

1,000 Bed Comprehensive Medical Center Launches ezBVA Lab Program Oak Ridge, TN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) capabilities through its ezBVA Lab service.

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
DXR
globenewswire.com03 September 2024

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 26th Annual Global Investment Conference being held on September 9-11, 2024 in New York City at the Lotte New York Palace Hotel.

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network
Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network
Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network
DXR
globenewswire.com29 August 2024

Community Hospital Purchases BVA Analyzer With Focus on Improving Outpatient Heart Failure Care Oak Ridge, TN, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology through the acquisition of the BVA analyzer. This advancement not only enhances revenue streams, but also sets the stage for projected accelerated sales growth for the rest of the year.

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
DXR
globenewswire.com05 August 2024

Daxor's ezBVA Lab Service Spearheads Growth and Broader Market Adoption Oak Ridge, TN, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA) in three new facilities. Daxor's ezBVA lab service is a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results.

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
DXR
globenewswire.com18 June 2024

Oak Ridge, TN, June 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22nd, 2024 at the Rosen Shingle Creek Resort in Orlando, Florida. The AAHFN is a specialty organization dedicated to advancing nursing education, clinical practice, and research to improve heart failure patient outcomes.

Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript
Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript
Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript
DXR
Seeking Alpha25 March 2024

Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript

Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DXR
GlobeNewsWire07 September 2023

Oak Ridge, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11 - 13, 2023 at the Lotte New York Palace.

FAQ

  • What is the primary business of Daxor?
  • What is the ticker symbol for Daxor?
  • Does Daxor pay dividends?
  • What sector is Daxor in?
  • What industry is Daxor in?
  • What country is Daxor based in?
  • When did Daxor go public?
  • Is Daxor in the S&P 500?
  • Is Daxor in the NASDAQ 100?
  • Is Daxor in the Dow Jones?
  • When was Daxor's last earnings report?
  • When does Daxor report earnings?
  • Should I buy Daxor stock now?

What is the primary business of Daxor?

Daxor Corporation, known as DXR, specializes in medical technology. They develop innovative blood volume measurement systems to help diagnose and manage various health conditions. Their products aim to improve patient care by providing accurate data for better treatment decisions in hospitals and clinics.

What is the ticker symbol for Daxor?

The ticker symbol for Daxor is NASDAQ:DXR

Does Daxor pay dividends?

No, Daxor does not pay dividends

What sector is Daxor in?

Daxor is in the Healthcare sector

What industry is Daxor in?

Daxor is in the Medical Instruments & Supplies industry

What country is Daxor based in?

Daxor is headquartered in United States

When did Daxor go public?

Daxor's initial public offering (IPO) was on 25 July 1983

Is Daxor in the S&P 500?

No, Daxor is not included in the S&P 500 index

Is Daxor in the NASDAQ 100?

No, Daxor is not included in the NASDAQ 100 index

Is Daxor in the Dow Jones?

No, Daxor is not included in the Dow Jones index

When was Daxor's last earnings report?

Daxor's most recent earnings report was on 29 August 2024

When does Daxor report earnings?

The next expected earnings date for Daxor is 25 March 2025

Should I buy Daxor stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions